Can you provide the last earnings date for ONCOCYTE CORP?
ONCOCYTE CORP (OCX) last reported earnings on 5/12/2025.
ONCOCYTE CORP (OCX) Earnings History & Surprises
NASDAQ:OCX • US68235C2061
Current stock price
3.2 USD
+0.47 (+17.22%)
At close:
3.17 USD
-0.03 (-0.94%)
After Hours:
OCX Earnings overview
Past quarterly earnings results for ONCOCYTE CORP (OCX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Aug 6, 2025
- Period
- Q2 / 2025
- EPS Estimate
- -$0.23
- Revenue Estimate
- 174.397K
Last Reported
Most Recent- Release Date
- May 12, 2025
- Period
- Q1 / 2025
- EPS Reported
- -$0.26
- EPS Surprise
- -8.85%
- Revenue Surprise
- 1,570.08%
Beat Rate
Last 8 Quarters 44%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2025 | -0.26 | -0.24 | -8.85% | 76.99% | 2.138M | 128.018K | 1,570.08% | 1,114.77% |
| Q4 2024 | -1.93 | -0.43 | -347.17% | 8.96% | 1.486M | 101K | 1,371.29% | 373.25% |
| Q3 2024 | -0.98 | -0.44 | -122.55% | -20.99% | 115K | 202K | -43.07% | -73.19% |
| Q2 2024 | -0.36 | -0.56 | 36.24% | 66.36% | 104K | 321.685K | -67.67% | -77.54% |
| Q1 2024 | -1.13 | -0.68 | -67.40% | -382.50% | 176K | 353.5K | -50.21% | -40.74% |
| Q4 2023 | -2.12 | -1.15 | -84.61% | 73.50% | 314K | 319.837K | -1.82% | 16.30% |
| Q3 2023 | -0.81 | -1.02 | 20.40% | 49.38% | 429K | 315.625K | 35.92% | 512.86% |
| Q2 2023 | -1.07 | -1.31 | 18.51% | 23.57% | 463K | 366.125K | 26.46% | 92.92% |
| Q1 2023 | 0.40 | -1.86 | 121.52% | 118.18% | 297K | 349.864K | -15.11% | -21.84% |
| Q4 2022 | -8.00 | -1.90 | -320.42% | -6,566.67% | 270K | 1.438M | -81.22% | 113.92% |
| Q3 2022 | -1.60 | -2.28 | 29.80% | -966.67% | 70K | 1.5M | -95.33% | -92.86% |
| Q2 2022 | -1.40 | -2.41 | 41.92% | -1,066.67% | 240K | 2.725M | -91.19% | -88.18% |
| Q1 2022 | -2.20 | -2.42 | 9.24% | -4,300.00% | 380K | 2.26M | -83.19% | -66.07% |
| Q4 2021 | -0.12 | -0.13 | 6.55% | -33.33% | -1.94M | 3.667M | -152.90% | -488.00% |
| Q3 2021 | -0.15 | -0.12 | -28.03% | -50.00% | 980K | 1.778M | -44.88% | 75.00% |
| Q2 2021 | -0.12 | -0.10 | -18.81% | 14.29% | 2.03M | 1.582M | 28.32% | 1,350.00% |
| Q1 2021 | -0.05 | -0.10 | 50.50% | 61.54% | 1.12M | 841.663K | 33.07% | 5,500.00% |
| Q4 2020 | -0.09 | -0.11 | 18.99% | - | 500K | 831.563K | -39.87% | - |
| Q3 2020 | -0.10 | -0.10 | -4.22% | - | 560K | 374.882K | 49.38% | - |
| Q2 2020 | -0.14 | -0.11 | -33.28% | - | 140K | 47.672K | 193.67% | - |
| Q1 2020 | -0.13 | -0.11 | -21.43% | - | 20K | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
1
Average EPS beat (4)
-110.58%
Max EPS beat (4)
36.24%
Min EPS beat (4)
-347.17%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
707.66%
Max Revenue beat (4)
1,570.08%
Min Revenue beat (4)
-67.67%
Analysis
In the last 4 quarters, OCX has beaten EPS estimates in 1 out of 4 releases
OCX has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, OCX reported -110.6% below the EPS estimates on average.
In the last 4 quarters, OCX has beaten the revenue estimates by 707.7% on average.
Related analysis
ONCOCYTE CORP / OCX Earnings FAQ
Did OCX stock beat earnings estimates in the most recent quarter?
ONCOCYTE CORP (OCX) missed EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does OCX stock beat earnings estimates?
In the last 4 quarters, ONCOCYTE CORP (OCX) has beaten EPS estimates in 1 out of 4 releases.